Patents
Literature
50 results about "Bicyclo Compounds" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bicyclic structures occur widely, for example in many biologically important molecules like α-thujene and camphor. A bicyclic compound can be carbocyclic (all of the ring atoms are carbons), or heterocyclic (the rings atoms consist of at least two different elements), like DABCO.
Bicyclic DGK Inhibitors
PendingUS20260001880A1Organic chemistryHeterocyclic compound active ingredientsDiseaseDiacylglycerol kinase
Owner:INCYTE CORP
Fused bicyclic compounds
The invention belongs to the field of medicinal chemistry, and relates to a fused bicyclic compound, in particular to a compound shown in a formula (II), a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound in treating diseases.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD
Substituted fused bicyclic compounds as kinase inhibitors and uses thereof
This invention provides substituted fused bicyclic compounds as kinase inhibitors and their applications, said substituted fused bicyclic compounds having the structure shown in Formula IIc, wherein R0, A1, A2, B1-B3, D1-D3, R7, and R8 are as defined herein. Compounds of Formula IIc are NUAK1 / 2 inhibitors. Therefore, the compounds of this invention can be used for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions, such as cancer, and for the preparation of medicaments for the treatment and prevention of NUAK1 / 2-mediated diseases, disorders, and conditions. (IIc)
Owner:IMPACT THERAPEUTICS (SHANGHAI) INC +1
BICYCLICAL COMPOUND AS A RIP-1 KINASE HIBITOR AND ITS USE
Owner:AFFAMED THERAPEUTICS (HK) LTD
Bicyclic compounds and their use in the treatment of diseases
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factor. In some embodiments, the compounds and compositions are provided for the treatment of diseases, including neurological disorders.
Owner:LEONABIO INC
Diastereo-and regio-selective alkenyl substituted bicyclic structures preparing from strained bicyclic alkene systems
Disclosed is a process for preparing asymmetrically substituted bicyclic compound of formula (III) or (IV) from a compound of formula (I) by pairing a compound of formula (II) with a carbene ligated transition-metal catalyst or a precursor in the presence of a hydride source, wherein the structure of the compound of formula (II) is used as one of the key factors that can alter the selectivity of (III) and (IV) under a given condition.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
BICYCLIC COMPOUNDS CONTAINING NITROGEN
Bicyclic nitrogen-containing compounds of Formula (I), pharmaceutical compositions comprising these compounds, and their use in the treatment of bacterial infections are described. (see Formula).
Owner:WOCKHARDT LTD
Linked bicyclic compounds as pesticides
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N‑oxides, and salts thereof, 1 wherein R1, R3, L, A and m are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling and combating an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the disclosure.
Owner:FMC CORP
Linked bicyclic compounds for combating and combating invertebrate pests
Disclosed are compounds having Formula 1, including all geometric and stereoisomers, N-oxides and salts thereof, where L, R1, m, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing these compounds of Formula 1, and methods for controlling and combating an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or composition of the disclosure.
Owner:FMC CORP
Bicyclic compound as rip-1 kinase inhibitor and application thereof
Owner:AFFAMED THERAPEUTICS (HK) LTD
Substituted bicyclic compounds as farnesoid x receptor modulators
Disclosed is a compound of Formula (I), or a stereoisomer, tautomer, or salt or solvate thereof, wherein all variables are as defined herein. The compounds modulate the activity of farnesoid X receptor (FXR), e.g., as agonists. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating diseases, disorders, or conditions associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
Owner:BRISTOL MYERS SQUIBB CO
Fused bicyclic EGFR inhibitors and methods of use thereof
The disclosure relates to fused bicyclic compounds comprising ring cores such as 2H-benzo[e][1,3]oxazin-4(3H)-one, 2,3-dihydrothieno[2,3-e][1,3]oxazin-4-one and 2,3-dihydrothieno[3,2-e][1,3]oxazin-4-one, that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds, optionally in combination with a second active agent; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
Owner:DANA FARBER CANCER INSTITUTE INC
Bicyclic compounds as CDK inhibitors
PendingCN121729412AOrganic active ingredientsOrganic chemistryBicyclo CompoundsCyclin-Dependent Kinase Inhibitors
Owner:BEIGENE (SUZHOU) CO., LTD.
Bicyclic-type mat2a inhibitor and use thereof
The present invention relates to a bicyclic-type MAT2A inhibitor and use thereof. Specifically, the present invention discloses a bicyclic compound represented by formula (I) or a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a racemate, an atropisomer, a polymorph, a solvate, or an isotope labeled compound thereof. The compound represented by formula (I) has MAT2A enzyme inhibitory activity, can be used as a good MAT2A inhibitor, and is further used for preparing drugs for treating and / or preventing MTAP-related diseases, especially tumors.
Owner:SHANGHAI HAIHE PHARMACEUTICAL CO LTD
Condensed piperidinyl bicyclic compounds and related compounds for use in the treatment of diseases
The present invention relates to condensed piperidinyl bicyclic, metasubstituted piperidinyl, and related compounds thereof that modulate the activity of the mammalian C5a receptor by directly binding to it, for use in treating diseases, particularly monosodium urate (MSU) induced diseases, neutrophil-induced inflammatory kidney diseases, cutaneous neutrophil inflammatory diseases, and immune complex diseases.
Owner:INFLARX
6,5-bicyclic compounds useful as CD38 inhibitors
The present invention relates to compounds that have activity as cluster of differentiation 38 (CD38) inhibitors, compositions of such compounds, and methods using such compounds for preventing or treating diseases and disorders such as, for example, diseases and disorders of metabolism.
Owner:NEOLAIA INC
Substituted Bicyclic Compounds, Compositions and Methods of Use
Owner:DEEP APPLE THERAPEUTICS INC
Bridged bicyclic compounds as BTK inhibitors
The present invention relates to bridged bicyclic Compounds A and B or their pharmaceutically acceptable salts thereof as inhibitors of Bruton's tyrosine kinase (BTK) and its C481 mutant. The present invention also relates to methods for preparing Compounds A and B or their pharmaceutically acceptable salts thereof. Compounds of the present invention can be used to treat and / or prevent related diseases mediated by BTK or its C481 mutant, especially cancer and autoimmune diseases.
Owner:BEIJING INNOCARE PHARMA TECH CO LTD
Heterobicyclic compounds as EP4 receptor antagonists
The invention is directed to a series of novel heterobicyclic amide derivatives as EP4 receptor antagonists which are useful for treating diseases or conditions mediated by the action of PGE2 at EP4 receptors, such as pain, an inflammatory disease and cancer. Also within the scope of this invention are pharmaceutical compositions containing such compounds and methods of use of these compounds for treating a subject suffering from a condition mediated by the action of PGE2 at EP4 receptors.
Owner:SHENZHEN IONOVA LIFE SCI CO LTD +2
Method of converting fischer-tropsch products into aromatics
PCT designated stageWO2026059786A1Catalytic naphtha reformingLiquid hydrocarbon mixture productionAlkaneNaphtha
Processes for converting Fischer-Tropsch products into aromatics are described. The processes involve processing a selected portion of the Fischer-Tropsch effluent or Fischer- Tropsch plus hydrocracking effluent in a separate, low pressure reforming reaction zone. The feed comprises the portion of the Fischer-Tropsch or Fischer-Tropsch / hydrocracking products boiling around the heavy naphtha and kerosene / light distillate range with a molecular composition of approximately Ce to Cie paraffins and iso-paraffins which would form alkylated mono or bicyclic compounds boiling in the naphtha-jet range.
Owner:UOP LLC
SOS1 inhibitors for treatment of philadelphia chromosome positive leukemia
The present disclosure provides methods for treating Philadelphia chromosome positive (Ph +) leukemia, such as CML (chronic myeloid leukemia, chronic myeloid leukemia, chronic myeloid SOS-1 inhibitors (such as bicyclic or macrocyclic compounds) of Ph + ALL (acute lymphoblastic leukemia), Ph + AML (acute lymphoblastic lymphoma), alone or in combination with TKI (such as dasatinib or imatinib) against BCR-ABL tyrosine kinases are disclosed.
Owner:KUMQUAT BIOSCIENCES INC
Novel heterobicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising same
PendingUS20260124197A1Organic active ingredientsOrganic chemistryPharmaceutical drugPharmaceutical medicine
Owner:HANMI PHARM CO LTD
Tertiary Amine Substituted Bicyclic Compounds Useful as T Cell Activators
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, R1, R2, R4, R5, and R6 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
Owner:BRISTOL MYERS SQUIBB CO
A five-membered and six-membered bicyclic compound, a preparation method and application thereof
The present disclosure provides a kind of five-membered and six-membered bicyclic compound, its preparation method and application.The present disclosure specifically provides a kind of compound as shown in formula (I) or its isomer, pharmaceutically acceptable salt, prodrug, solvate, isotopically labeled derivative, metabolite, nitrogen oxide, its preparation method and the pharmaceutical composition containing the compound, and its application in the preparation of treating disease drugs.
Owner:SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD
Methods of using bicyclic compounds as triggering receptor expressed on myeloid cells (TREM2) agonists
The present disclosure provides methods of using a small molecule TREM2 agonist or a pharmaceutically acceptable salt thereof to treat Alzheimer's Disease in a human subject.
Owner:VIGIL NEUROSCIENCE INC
Heteroaromatic and heterobicyclic compounds as pkmyt1 inhibitors and uses thereof
The present application provides heteroaromatic ring and heterobicyclic compounds as PKMYT1 inhibitors and uses thereof. Specifically, the present application provides a compound of the following Formula I, a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, an isotopically-labeled compound, or a pharmaceutically acceptable salt thereof, or a mixture thereof, in which each group is as described herein. The compounds of the present application are PKMYT1 kinase inhibitors, which can treat or prevent a disease or disorder caused by abnormal PKMYT1 activity, or for use in the manufacture of a medicament for treating or preventing a disease or disorder caused by abnormal PKMYT1 activity.
Owner:IMPACT THERAPEUTICS (SHANGHAI) INC +1
PCSK9 and HMG-coa bicyclic compound, and preparation and use thereof
The present invention relates to the technical field of chemical drugs, and in particular to a PCSK9 and HMG-CoA bicyclic compound, or an isomer, racemate or pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof. The present invention further relates to a use of the PCSK9 and HMG-CoA bicyclic compound as a PCSK9 inhibitor and / or an HMG-CoA reductase inhibitor, and a method for the treatment of multiple specific diseases or conditions using the PCSK9 and HMG-CoA bicyclic compound.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD
Bicyclic compounds and their use in the treatment of Pitt-Hopkins syndrome
Owner:NEUREN PHARMA INC